Global Non-Small Cell Lung Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035

Global Non-Small Cell Lung Cancer Market Outlook

Thelansis's "Global Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Small Cell Lung Cancer treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Non-Small Cell Lung Cancer Overview

Non-small cell lung cancer (NSCLC) is the most prevalent lung malignancy, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, driven by diverse oncogenic alterations including EGFR mutations, ALK and ROS1 rearrangements, KRAS G12C mutations, MET exon 14 skipping, RET fusions, and BRAF V600E mutations alongside PD-L1 overexpression. Tobacco smoking remains the dominant risk factor, though never-smoker adenocarcinoma with targetable driver mutations represents a growing subpopulation. Patients present with persistent cough, haemoptysis, dyspnoea, and constitutional symptoms, with many diagnosed at advanced stages. Comprehensive next-generation sequencing and PD-L1 immunohistochemistry are mandatory at diagnosis. Pembrolizumab monotherapy is standard for high PD-L1 expressors, while chemoimmunotherapy addresses lower expressors. EGFR-mutated disease is addressed with osimertinib monotherapy or the amivantamab plus lazertinib combination, including a recently approved subcutaneous formulation, which has fundamentally redefined frontline standards by delivering superior progression-free survival over monotherapy. ALK is addressed with alectinib, ROS1 with entrectinib, KRAS G12C with adagrasib, MET with tepotinib, RET with selpercatinib, and BRAF V600E with dabrafenib-trametinib. Surgical resection remains curative for localised disease, with adjuvant osimertinib improving survival in resected EGFR-mutated NSCLC. Prognosis varies markedly with stage and molecular subtype; multidisciplinary management, smoking cessation, and patient-centred supportive care are integral to optimising outcomes.

Key Highlights

• In Germany, survival-adjusted prevalent cases of Non-Small Cell Lung Cancer (NSCLC) are projected to increase from 497,473 patients in 2025 to 532,039 patients by 2035, reflecting improved survival outcomes and growing disease burden.
• NSCLC remains the most common subtype of lung cancer, accounting for the majority of lung cancer diagnoses and mortality worldwide.
• Increasing adoption of molecular diagnostics and biomarker testing is enabling broader use of precision oncology approaches in Germany.
• Treatment paradigm has significantly shifted toward targeted therapies and immuno-oncology agents, improving progression-free and overall survival outcomes.
• Persistent unmet need exists in resistant mutations, late-stage diagnosis, metastatic disease progression, and treatment sequencing optimization.
• Growing focus on KRAS, EGFR, ALK, HER2, and PD-(L)1 targeted therapies is expected to further transform the competitive landscape over the forecast period.

Market Overview

• The France NSCLC market is projected to grow from USD 1.3 billion in 2025 to USD 3.2 billion by 2035, indicating strong market expansion driven by innovation in oncology therapeutics.
• Market growth is driven by:
• Rising adoption of premium-priced targeted therapies and immunotherapies
• Increasing biomarker-driven treatment eligibility and personalized medicine approaches
• Improved survival rates leading to longer treatment duration
• Market value is supported by continuous launch of next-generation oncology agents and expanding utilization of combination treatment regimens.
• A robust pipeline of novel targeted therapies, antibody-drug conjugates (ADCs), and next-generation checkpoint inhibitors is expected to create significant commercial opportunities.
• Future growth will depend on advancements in early detection, overcoming therapeutic resistance, and improving long-term survival in advanced and metastatic NSCLC patients.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle Eas

Companies Mentioned

• Pfizer
• Merck Sharp & Dohme LLC
• AstraZeneca
• GlaxoSmithKline
• BeiGene
• Arcus Biosciences, Inc.
• AbbVie
• STCube, Inc.
• Avistone Biotechnology Co., Ltd.
• Regeneron Pharmaceuticals
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• Daiichi Sankyo
• Akeso
• Bristol-Myers Squibb
• RemeGen Co., Ltd.
• BioNTech SE
• Hoffmann-La Roche
• Nuvation Bio Inc.
• TJ Biopharma Co., Ltd.
• Klus Pharma Inc.
• Henan Genuine Biotech Co., Ltd.
• Gilead Sciences
• Genentech, Inc.
• Revolution Medicines, Inc.
• Servier Bio-Innovation LLC
• Summit Therapeutics
• Chipscreen Biosciences, Ltd.
• Eli Lilly and Company
• Integro Theranostics
• Amgen
• Tango Therapeutics, Inc.
• Verastem, Inc.
• Nuvalent Inc.
• ArriVent BioPharma, Inc.
• IO Biotech
• Betta Pharmaceuticals Co., Ltd.
• Replimune, Inc.
• ImmunityBio, Inc.